Combination Therapy With Baricitinib And Narrowband Ultraviolet B For Active Non-Segmental Vitiligo: A Retrospective Controlled Study

This study evaluated the efficacy and tolerability of combining baricitinib, a JAK1/2 inhibitor, with narrowband UV-B (NB-UVB) therapy in treating active nonsegmental vitiligo (NSV). Involving 52 patients in the combination group and 49 in the control group receiving oral mini-pulse methylprednisolone with NB-UVB, the study found that the combination therapy was effective and well-tolerated over a 6-month period. Recurrence rates within 6 months post-treatment were similar between groups. Minor adverse effects included itchy skin in 5.8% and erythema in 1.9% of patients in the combination group. The findings suggest this combination therapy is a promising treatment option for NSV, supporting the need for larger clinical trials.